Friday, 16 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 2, 2026

Medtronic Diabetes expands access to full-stack insulin delivery solutions with Medicare access and new FDA clearances

View original at finance.yahoo.com
Medtronic Diabetes expands access to full-stack insulin delivery solutions with Medicare access and new FDA clearances GALWAY, Ireland, Feb…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Bringing together the Instinct sensor with the well-established algorithm of the MiniMed 780G system makes for an extremely effective combination

    80% confidence

  • Medtronic technologies and therapies treat 70 health conditions and transform the lives of two people every second, every hour, every day

    80% confidence

  • By broadening sensor and insulin options for the MiniMed 780G system, more people will benefit from automated insulin delivery that supports easier mealtimes, greater flexibility, and more confident diabetes management

    80% confidence

  • More people living with type 2 diabetes will get access to life-changing technology improving their day-to-day experience in managing their diabetes

    80% confidence

  • Ultra rapid-acting insulin's faster onset may help reduce the impact of late or missed meal doses, allowing the insulin to catch up more effectively

    80% confidence

  • MiniMed 780G system automatically adjusts insulin delivery every five minutes, responding to glucose changes, supporting more stable glucose control with fewer highs and lows and less daily decision-making

    80% confidence

  • These milestones reflect unwavering commitment to expanding access and giving individuals living with diabetes more choice in how they manage their condition

    80% confidence

  • Instinct sensor offers up to 15 days of wear and is the world's smallest and thinnest integrated CGM

    80% confidence

  • Anyone who requires insulin therapy to manage their diabetes, whether type 1 or type 2, can benefit from automated insulin delivery

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com
Medtronic Diabetes expands access to full-stack insulin delivery solutions with Medicare access and new FDA clearances — Source | Via News | ViaNews EU